-
Mashup Score: 4Is It Ever OK to Have an 8 a.m. Meeting? - 2 month(s) ago
Employees want flexibility in their work-life schedules, while employers focus on the business needs.
Source: www.wsj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade - 2 month(s) ago
Nabet et al. utilize RNA-seq from a large randomized SCLC clinical trial to identify four patient subsets with distinct neuroendocrine (NE) phenotypes, immune composition, and benefit from immunotherapy. In the two T cell-inflamed subsets, NE tumors with low macrophages benefit from immunotherapy compared to non-NE tumors with high macrophages.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
RT @Barzin_: Excited to share our paper led by our team at @Genentech out in @Cancer_Cell: https://t.co/bYy6swTFlw where we dig into pre-tr…
-
-
Mashup Score: 29Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade - 3 month(s) ago
Nabet et al. utilize RNA-seq from a large randomized SCLC clinical trial to identify four patient subsets with distinct neuroendocrine (NE) phenotypes, immune composition, and benefit from immunotherapy. In the two T cell-inflamed subsets, NE tumors with low macrophages benefit from immunotherapy compared to non-NE tumors with high macrophages.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
RT @Barzin_: Excited to share our paper led by our team at @Genentech out in @Cancer_Cell: https://t.co/bYy6swTFlw where we dig into pre-tr…
-
-
Mashup Score: 2Cancer Research Public Workshop - 3 month(s) ago
Hybrid Event
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
Great public workshop today and tomorrow, available by webcast. https://t.co/7B6tbk8lR4 Lots of great speakers https://t.co/cLZWlKXC3b
-
-
Mashup Score: 45Selpercatinib or Chemotherapy in RET Fusion–Positive NSCLC | NEJM - 3 month(s) ago
Correspondence from The New England Journal of Medicine — Selpercatinib or Chemotherapy in RET Fusion–Positive NSCLC
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Provocative question and response in @NEJM about ethical justification for randomized trial of selpercatinib https://t.co/2B1wt2QnqT https://t.co/BGESsrY6Pp
-
-
Mashup Score: 5
Dr. Maria Carlo received a 2023 KCA Trailblazer Award for research on the “Role of germline and somatic variants in NRF2 pathway genes in renal cell
Source: www.kidneycancer.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrRosenbergMSK: Congratulations to Dr. Carlo- very well deserved! https://t.co/eWW5vdrF71
-
-
Mashup Score: 5
Dr. Maria Carlo received a 2023 KCA Trailblazer Award for research on the “Role of germline and somatic variants in NRF2 pathway genes in renal cell
Source: www.kidneycancer.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrRosenbergMSK: Congratulations to Dr. Carlo- very well deserved! https://t.co/eWW5vdrF71
-
-
Mashup Score: 27Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers - 6 month(s) ago
Cancer genomes from patients with African (AFR) ancestry have been poorly studied in clinical research. We leverage two large genomic cohorts to inves…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Very interesting work from a huge team (led by @CarrotJian from @MSKCancerCenter) on associations between %African ancestry and tumor genomics. In particular, they note⬇️KRAS G12C and EGFR L858R, and ⬆️ROS1 fusion with ⬆️african ancestry in lung cancers" https://t.co/O8ZmZrHzr5 https://t.co/RUUMD96G1F
-
-
Mashup Score: 1Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non–Small-Cell Lung Cancer - 7 month(s) ago
The treatment landscape of epidermal growth factor receptor (EGFR)–mutant advanced NSCLC has rapidly evolved. Third-generation tyrosine kinase inhibitors (TKIs) are now the preferred standard treatment option in the first-line setting 1 on the b asis of prolonged progression-free survival (PFS) and superior intracranial activity when compared with first-generation epidermal growth factor receptor (EGFR) TKIs. 2 – 7 Unfortunately, resistance inevitably develops. Although several mechanisms of acquired
Source: ascopubs.orgCategories: Latest Headlines, Oncologists1Tweet-
Speeding up Antibody-Drug Conjugate Development in Pretreated EGFR-Mutant Non–Small-Cell Lung Cancer by @JordiRemon and Lizza Hendriks https://t.co/cbL4QqR63s
-
-
Mashup Score: 0
Nature – Wide distribution of findings shows how analytical choices drive conclusions.
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Always fascinating to see these sorts of analyses. Send same data set to multiple scientists and see what their conclusions are...they don't all agree! https://t.co/JoGBcoykF1
-
WSJ: ⬇️ Everyone in medicine: LOL🤣 https://t.co/tGlppQ5dJM via @WSJ https://t.co/2VlCq9pN8a